Advances in first-line treatment of chronic lymphocytic leukemia: current recommendations on management and first-line treatment by the German CLL Study Group (GCLLSG)

European Journal of Haematology
Paula CramerM Hallek

Abstract

The management of patients with CLL is undergoing significant changes; during the last decade, the outcome of first-line therapies has been markedly improved with the addition of anti-CD20 antibodies to chemotherapy. Today, chemoimmunotherapy for physically fit patients ≤ 65 years should consist of fludarabine, cyclophosphamide, and rituximab (FCR). The combination of bendamustine and rituximab (BR) should be considered in physically fit patients > 65 years and in patients with a higher risk of infections. Patients with reduced fitness and/or relevant comorbidity should receive chlorambucil with a CD20 antibody, preferably obinutuzumab. Regardless of their fitness, patients with CLL carrying genetic aberrations such as del(17p) and/or TP53 mutation poorly respond to chemoimmunotherapy and therefore require different therapeutic approaches. An increasing understanding of the disease biology has led to the development of targeted drugs for the treatment of CLL, such as the BTK inhibitor ibrutinib and PI3K inhibitor idelalisib. These agents have shown efficacy in high-risk and relapsed/refractory patients and are currently being evaluated in clinical trials for first-line therapy. It is anticipated that these compounds and further...Continue Reading

References

Jan 1, 1991·Genes, Chromosomes & Cancer·D OscierR Lambert
May 1, 1968·Journal of the American Geriatrics Society·B S LinnL Gurel
Jul 8, 2000·The Oncologist·L Balducci, M Extermann
Dec 15, 2000·The New England Journal of Medicine·K R RaiC A Schiffer
Jan 3, 2001·The New England Journal of Medicine·H DöhnerP Lichter
Mar 16, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Michael J KeatingHagop Kantarjian
Sep 10, 2005·Blood·Lindsay M MortonMartha S Linet
Nov 17, 2006·Leukemia·P DregerUNKNOWN Chronic Leukemia Working Party of the EBMT
Jan 24, 2007·CA: a Cancer Journal for Clinicians·Ahmedin JemalMichael J Thun
Jan 24, 2007·Cancer Control : Journal of the Moffitt Cancer Center·Lodovico Balducci
Feb 7, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Ian W FlinnMartin S Tallman
Nov 7, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Peter HillmenJiri Mayer
Jul 12, 2008·European Journal of Haematology·Louise WatsonDaniel Catovsky
Aug 9, 2008·The New England Journal of Medicine·Andy C RawstronPeter Hillmen
Nov 7, 2008·The New England Journal of Medicine·Christopher S MulliganStephen P Mulligan
Dec 17, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Kenneth A FoonAhmad Tarhini
Feb 7, 2009·Leukemia & Lymphoma·Barbara EichhorstMichael Hallek
Aug 5, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Wolfgang U KnaufMarco Montillo
Aug 26, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Francesc BoschEmili Montserrat
Oct 17, 2009·Blood·John G Gribben
Mar 3, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Tadeusz RobakSergey I Moiseev
Oct 20, 2010·Nature Reviews. Clinical Oncology·Paula Cramer, Michael Hallek
Apr 19, 2011·Blood·William G WierdaUNKNOWN 407 Study Investigators

❮ Previous
Next ❯

Citations

Apr 22, 2016·Current Treatment Options in Oncology·Nathan SinghShannon L Maude
Aug 18, 2016·Clinical Immunology : the Official Journal of the Clinical Immunology Society·Marianne Engelhard
Jul 12, 2017·Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners·Jacqueline L OlinMorgan B Smith
Aug 8, 2018·Expert Opinion on Biological Therapy·Mitchell EversJ H W Leusen
Feb 15, 2020·Cancer Immunology, Immunotherapy : CII·Denise RisnikMirta Giordano
Jul 29, 2017·Nature Communications·Gero KnittelH Christian Reinhardt
Oct 22, 2020·International Journal of Molecular Sciences·Katarzyna SzoltysekMeera Soundararajan

❮ Previous
Next ❯

Related Concepts

Related Feeds

B-Cell Leukemia (Keystone)

B-cell leukemia includes various types of lymphoid leukemia that affect B cells. Here is the latest research on B-cell leukemia.

AKT Pathway

This feed focuses on the AKT serine/threonine kinase, which is an important signaling pathway involved in processes such as glucose metabolism and cell survival.